GLP-1 use surges as surgery rates drop for severe obesity

GLP-1 prescriptions for severe obesity surged from fewer than 4,600 in 2018 to more than 1.4 million in 2025, while bariatric surgery rose more slowly from under 20,000 to almost 43,000 in 2023 before slipping below 40,000 in 2024 and 2025. Despite the growth in treatment, 90% to 95% of patients still received no obesity therapy, highlighting a large unmet market. The findings are broadly supportive for GLP-1 adoption but also indicate persistent access and affordability barriers across the obesity treatment continuum.

Analysis

The market is still underestimating the second-order winner from obesity pharmacotherapy: not the drug makers alone, but the downstream ecosystem that monetizes chronic follow-up, titration, and failed first-line therapy. If GLP-1s keep pulling share from surgery, the immediate pressure is on bariatric centers, hospital outpatient departments, and device suppliers tied to procedure volumes; however, the larger economic effect is likely a longer duration of obesity management spend per patient, which favors firms with adherence tools, remote monitoring, and primary-care distribution leverage. In other words, the mix shift is away from one-time procedural revenue and toward recurring pharmaceutical and service revenue.

The key incremental signal is that the decline in surgery appears to be happening at the severe end of the funnel, which is where the highest-acuity patients drive disproportionate revenue and complexity. That matters because it raises the possibility that surgical centers see not just volume pressure but adverse case mix: easier-to-serve patients migrate to meds first, while the remaining surgical population becomes sicker, more expensive, and potentially less profitable. Over a 12-24 month horizon, that can compress margins even if headline procedure counts only drift lower.

The contrarian angle is that the penetration data argues for a much slower displacement than current obesity-stock narratives imply. With the vast majority still untreated, the debate is not GLP-1s versus surgery so much as whether the system can convert latent demand into any therapy at all. If payer tightening, supply normalization, or GI side effects cap persistence, surgery could reassert itself as the durable solution for the highest-BMI cohort, making the recent procedural softness look like a temporary substitution rather than structural erosion.

Key Decisions for Investors

• Short/protectively hedge procedural exposure: fade names levered to bariatric volume and outpatient surgery mix over the next 3-6 months; use a basket short in hospitals with outsized bariatric contribution or buy puts on relevant surgery-center names if liquidity permits. Risk/reward: asymmetrical to the downside if GLP-1 access broadens further; thesis breaks if payer restrictions tighten or GLP-1 discontinuation rises.
• Long the chronic-care winners: accumulate LLY/NVO on weakness for a 6-12 month horizon, but express via call spreads to avoid paying full multiple for already-consensus obesity growth. Risk/reward: upside comes from persistence/expansion into earlier-line obesity treatment; risk is valuation compression if growth shifts from launch to normalization.
• Pair trade: long pharma obesity exposure vs short device/procedure beneficiaries of bariatric surgery. The setup works best if GLP-1 utilization continues to outgrow surgery at a multi-year pace. Use as a relative-value hedge against a broad healthcare correction.
• Watch for a reversal catalyst in 2H: payer prior-authorization tightening, GLP-1 supply normalization, or Medicare/large-employer coverage changes could lift surgery volume back quickly. If those appear, cover short surgery exposure aggressively because the operating leverage in procedure names can re-rate fast.
• Consider a small tactical long in remote obesity-management / adherence enablers if liquid: the real bottleneck becomes persistence, not initiation. Best risk/reward is in businesses that increase refill rates and reduce dropout, since those economics compound across the entire treated cohort.